CoChat

Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease

Yaghoubi, Malek, Jafari, Sattar, Sajedi, Behnam, Gohari, Sepehr, Akbarieh, Samira, Heydari, Amir H., Jameshoorani, Maryam · 2017 · European Journal of Gastroenterology & Hepatology
Cited by 45

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) is known to be a health-related problem; there is no proven treatment for NAFLD. However, a wide range of possible therapies have been proposed and studied. In the current study, we aimed to compare the therapeutic effects of fenofibrate and pioglitazone on NAFLD. Patients and methods: In this randomized clinical trial study (ethic number: ZUMS.REC.1393.133), patients with NAFLD and alanine aminotransferase in range of 1–1.5 folds of normal and BMI (25–35) were studied. Blood lipids and liver enzymes were measured. The patients were divided randomly into three groups (recipient of fenofibrate, pioglitazone, and exercise). After the patients completed the course of treatment, liver enzymes were measured. Results: According to the results of this study, 90 patients with NAFLD were divided into three groups of 30 patients. All variables at the beginning of the study showed no significant difference among the three groups, but after the treatment period, the results showed that the levels of alanine aminotransferase, aspartate transaminase, systolic blood pressure, diastolic blood pressure, and BMI changed significantly: the levels decreased in all groups. Conclusion: This study showed beneficial effects of fenofibrate and pioglitazone in patients with fatty liver. Further studies with larger study populations on the effects of these drugs on fatty liver, lipid profile, blood glucose, and insulin are suggested.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/meg.0000000000000981

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 45

Metadata

Authors
Yaghoubi, M., Jafari, S., Sajedi, B., Gohari, S., Akbarieh, S., Heydari, A. H., & Jameshoorani, M.
Venue
European Journal of Gastroenterology & Hepatology
Published
2017-12
Volume
29
Issue
12
Pages
1385-1388
ISSN
0954-691X (ISSN-L)
OpenAlex
W2761855352
Cited by
45
References
2
FWCI
2.04
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1097/meg.0000000000000981
The paper
Yaghoubi, M., Jafari, S., Sajedi, B., Gohari, S., Akbarieh, S., Heydari, A. H., & Jameshoorani, M. (2017). Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/meg.0000000000000981

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.